Poziotinib

Poziotinib
Legal status
Legal status	experimental;
Identifiers
	IUPAC name 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one;
CAS Number	1092364-38-9;
PubChem CID	25127713;
ChemSpider	30687714;
UNII	OEI6OOU6IK;
KEGG	D12229;
ChEBI	CHEBI:195559;
CompTox Dashboard (EPA)	DTXSID80148853 ;
Chemical and physical data
Formula	C23H21Cl2FN4O3
Molar mass	491.34 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=C(C=C2C(=C1)N=CN=C2NC3=C(C(=C(C=C3)Cl)Cl)F)OC4CCN(CC4)C(=O)C=C;
	InChI InChI=1S/C23H21Cl2FN4O3/c1-3-20(31)30-8-6-13(7-9-30)33-19-10-14-17(11-18(19)32-2)27-12-28-23(14)29-16-5-4-15(24)21(25)22(16)26/h3-5,10-13H,1,6-9H2,2H3,(H,27,28,29); Key:LPFWVDIFUFFKJU-UHFFFAOYSA-N;

Poziotinib (NOV120101, HM781-36B)^[1] is a drug in development by Hanmi Pharmaceutical (in South Korea), Luye Pharma (China), and Spectrum Pharmaceuticals (rest of world) for various cancers.^[2]

Legal status

experimental

CAS Number

1092364-38-9

PubChem CID

25127713

ChemSpider

30687714

Quick facts Legal status, Identifiers ...

Close

It is built on an anilino-quinazoline scaffold and inhibits the epidermal growth factor receptors EGFR, HER2/neu, and Her 4^[3] and binds covalently to its targets.^[4]

It was discovered at Hanmi; in August 2014 Hanmi exclusively licensed rights in China to the Chinese company Luye Pharma and in February 2015 Hanmi licensed rights in the rest of the world outside of South Korea to Spectrum.^[2]

As of 2016 Spectrum had started a Phase II trial of poziotinib a second-line treatment for breast cancer.^[2]

[1]

[2]

[3]

[4]

Poziotinib

References

Related Articles